DEFA14A: Metsera Board Deems Novo Nordisk Bid Superior to Pfizer's

Metsera's Board of Directors has determined that Novo Nordisk's revised acquisition proposal, valuing the company at up to $86.20 per share, constitutes a superior offer compared to Pfizer's latest proposal.

Summary

• Metsera's Board of Directors declared Novo Nordisk's revised proposal a "Superior Company Proposal" over the existing Pfizer Merger Agreement.
• The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion.
• This represents an approximate 159% premium to Metsera's closing price on September 19, 2025.
• The Novo Nordisk proposal includes an upfront cash payment of $62.20 per share and a Contingent Value Right (CVR) of up to $24.00 per share.
• The CVR milestones for Novo Nordisk are: $5.25 for Phase 3 clinical trial start (MET-097i and MET-233i combination), $7.50 for Mono FDA approval (monthly MET-097i monotherapy), and $11.25 for Combination FDA approval (monthly MET-097i and MET-233i combination).
• Pfizer's revised proposal offered $60.00 per share in cash and a CVR of up to $10.00 per share, valuing Metsera at up to $70.00 per share, totaling approximately $8.1 billion.
• Pfizer's CVR milestones were reduced to: $2.75 for Phase 3 clinical trial start, $4.25 for Mono FDA approval, and $3.00 for Combination FDA approval.
• The Pfizer revised proposal also included a requirement for a Metsera shareholder to sell 14.9% of common stock to Pfizer upon signing and for Metsera to issue a press release deeming the Novo Nordisk proposal unviable.
• The Novo Nordisk proposal expires at 10:00 a.m. Eastern Time on November 6, 2025.
• Metsera has initiated a two-business-day negotiation period with Pfizer as per the existing merger agreement.
• Metsera's Board reaffirms its recommendation for the Pfizer Merger Agreement at this time, but no shareholder action is required.
• Metsera expects the dividend from the Novo Nordisk proposal to be treated as a return of capital for U.S. federal tax purposes, then capital gain, subject to final determination of 2025 earnings and profits.

Sentiment

Score: 8

Explanation: The filing indicates a highly positive development for Metsera shareholders due to a significantly improved acquisition offer from Novo Nordisk, which has been deemed superior to Pfizer's revised proposal. The increased cash and CVR components, along with the substantial premium, suggest a strong valuation for the company's assets. However, the ongoing negotiation period with Pfizer and the potential for further competitive actions introduce some uncertainty.

Positives

• Novo Nordisk's revised proposal offers a higher total value of up to $86.20 per share, compared to Pfizer's revised offer of up to $70.00 per share.
• The Novo Nordisk proposal represents a significant premium of approximately 159% to Metsera's closing price on September 19, 2025.
• The cash component of the Novo Nordisk offer is higher at $62.20 per share upfront, compared to Pfizer's $60.00 per share.
• The Contingent Value Right (CVR) component of the Novo Nordisk offer is substantially higher at up to $24.00 per share, compared to Pfizer's reduced CVR of up to $10.00 per share.
• The CVR milestones in the Novo Nordisk proposal offer higher potential payouts for clinical trial start ($5.25 vs $2.75), mono FDA approval ($7.50 vs $4.25), and combination FDA approval ($11.25 vs $3.00).
• The Board's determination of a "Superior Company Proposal" indicates a strong competitive bidding environment for Metsera, potentially leading to an even better offer.

Negatives

• The existing Pfizer Merger Agreement remains in effect, creating uncertainty about the final outcome.
• Pfizer's revised proposal included a demand for Metsera to issue a press release stating the Novo Nordisk proposal was unacceptably high risk and unviable, which could indicate potential contentious negotiations.
• Pfizer's revised proposal also included a term for a shareholder of Metsera to sell 14.9% of common stock to Pfizer upon signing, which could be seen as an attempt to lock in a significant stake.
• The tax treatment of the potential dividend from the Novo Nordisk proposal is subject to final determination of 2025 earnings and profits, leading to some uncertainty for shareholders, particularly non-U.S. holders who may face 30% withholding.

Risks

• Risks related to the satisfaction or waiver of conditions to closing the proposed acquisition, including failure to obtain necessary regulatory approvals and requisite stockholder vote.
• Possibility that the proposed acquisition does not close.
• Possibility that more competing offers may be made, prolonging uncertainty.
• Risks related to the ability to realize anticipated benefits of the proposed acquisition, including benefits not being realized or not within the expected timeframe.
• Risk that businesses will not be integrated successfully.
• Disruption from the transaction making it more difficult to maintain business and operational relationships, including Metsera's ability to attract and retain highly qualified management and clinical/scientific personnel.
• Negative effects of the announcement or consummation of the proposed acquisition on the market price of Pfizer's or Metsera's common stock and/or operating results.
• Significant transaction costs and unknown liabilities.
• Risk of litigation and/or regulatory actions related to the proposed acquisition, including expenses from defending litigation, potential damages, and impact on the company and its stock price.
• Other business effects and uncertainties, including industry, market, business, economic, political, or regulatory conditions.
• Future exchange and interest rates.
• Risks and uncertainties related to issued or future executive orders or other new, or changes in, laws, regulations, or policy; changes in tax and other laws, regulations, rates, and policies.
• Uncertainties inherent in business and financial planning, including risks related to Pfizer's business and prospects, adverse developments in markets, or adverse developments in capital markets, credit markets, regulatory environment, tariffs, and trade policies.
• Uncertainties regarding the commercial success of Metsera's pipeline products or Pfizer's commercialized and/or pipeline products.
• Risks associated with Metsera conducting clinical trials and preclinical studies outside of the United States.
• Metsera's reliance on third parties for clinical trials, preclinical studies, manufacturing, and shipping of product candidates.
• Risk that Metsera's product candidates are associated with side effects, adverse events, or other properties or safety risks.
• Risks associated with Metsera's license and collaboration agreements and future strategic alliances.
• Metsera's ability to obtain, maintain, defend, and enforce patent or other intellectual property protection for current or future product candidates or technology.
• Uncertainties inherent in research and development, including meeting anticipated clinical endpoints, commencement/completion dates for clinical trials, regulatory submission/approval/launch dates, unfavorable new clinical data, and further analyses of existing data.
• Risks associated with initial, preliminary, or interim data.
• Risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities.
• Uncertainty whether regulatory authorities will be satisfied with the design and results from clinical studies.
• Uncertainty whether and when drug applications may be filed or approved in any jurisdictions for pipeline products.
• Decisions by regulatory authorities impacting labeling, manufacturing processes, safety, and/or other matters that could affect product availability or commercial potential.
• Uncertainties regarding the impact of COVID-19.
• Competitive developments.

Future Outlook

Metsera anticipates updating information on the taxation of the potential dividend following the completion of its 2025 financial results and a review of other factors. The company also expects to continue negotiations with Pfizer during a two-business-day period to see if Pfizer will adjust its offer to match or exceed Novo Nordisk's superior proposal.

Management Comments

• Metsera's Board of Directors determined, after consultation with its outside counsel and financial advisors, that a revised proposal from Novo Nordisk A/S to acquire Metsera constitutes a Superior Company Proposal as defined in Metsera's existing Merger Agreement with Pfizer.
• At this time, the Pfizer Merger Agreement remains in full effect, and Metsera's Board of Directors reaffirm their recommendation that the holders of Metsera common stock approve the adoption of the Pfizer Merger Agreement and approve the Merger with Pfizer on the terms and subject to the conditions set forth in the Pfizer Merger Agreement. However, no action by Metsera shareholders is required at this time.
• Metsera does not believe it has a meaningful amount of earnings and profits. As such, Metsera currently expects that, for U.S. federal tax purposes, the Dividend will be treated first, as a return of capital to shareholders to the extent of their tax basis in their Metsera common stock, and thereafter as capital gain from the sale or exchange of Metsera stock.

Industry Context

This announcement highlights the intense competition within the pharmaceutical and biotechnology sectors for promising pipeline assets, particularly those in late-stage clinical development like Metsera's MET-097i and MET-233i. The bidding war between major players like Pfizer and Novo Nordisk underscores the strategic importance of these assets for future growth and market positioning, especially in areas with high unmet medical needs. The use of Contingent Value Rights (CVRs) is a common mechanism in biotech M&A to bridge valuation gaps and share future development risks and rewards, reflecting the inherent uncertainties in drug development.

Comparison to Industry Standards

• The bidding war between Novo Nordisk and Pfizer for Metsera is consistent with recent trends in the pharmaceutical industry where large pharmaceutical companies are actively acquiring smaller biotech firms with innovative pipelines to replenish their own.
• The use of CVRs in both proposals aligns with industry practices for valuing pre-commercial assets, where future payments are tied to specific clinical and regulatory milestones, such as FDA approvals for MET-097i monotherapy and MET-097i/MET-233i combination, similar to deals seen with companies like BioNTech or Moderna during their early development phases.
• The premium offered by Novo Nordisk (159% over Metsera's closing price on September 19, 2025) is substantial, reflecting the high strategic value placed on Metsera's assets, comparable to premiums observed in other competitive biotech acquisitions where multiple bidders are involved.
• Pfizer's attempt to reduce the CVR value while increasing upfront cash, and demanding a press release discrediting Novo Nordisk, indicates aggressive competitive tactics, which are not uncommon in high-stakes M&A battles in the pharma sector.

Legal Proceedings

• Risks related to litigation and/or regulatory actions related to the proposed acquisition, including expenses from defending the litigation, potential damages or other losses, and the impact on the company, its business, and stock price.
• Risks relating to Pfizer's litigation against the Company, including expenses from defending the litigation, potential damages or other losses resulting from the litigation, the impact of the litigation on the Company, its business and the market price of the Company's common stock and the impact of the litigation on Novo Nordisk's unsolicited proposal.

Stakeholder Impact

• Shareholders: Potential for significantly higher acquisition value (up to $86.20 per share from Novo Nordisk vs. up to $70.00 from Pfizer), including a substantial premium and a higher cash component. Uncertainty regarding the final acquirer and the tax treatment of a potential dividend.
• Employees: Potential for disruption from the transaction, making it more difficult to attract and retain highly qualified management and other clinical and scientific personnel.
• Customers/Suppliers: Potential for changes in business and operational relationships due to the acquisition.
• Creditors: No specific impact mentioned, but general business uncertainties could indirectly affect creditworthiness.

Next Steps

• Metsera will notify Pfizer of the "Superior Company Proposal" determination.
• A two-business-day period will commence during which Pfizer has the right to negotiate adjustments to the Pfizer Merger Agreement.
• If, after this period, Metsera's Board still concludes Novo Nordisk's proposal is superior, Metsera would be entitled to terminate the Pfizer Merger Agreement.
• Metsera expects to update information on the taxation of the dividend following the completion of 2025 financial results.
• Shareholders are urged to read preliminary and definitive proxy statements and other related documents filed with the SEC before making any voting decision.

Key Dates

Recommendation

The filing clearly indicates a competitive bidding situation where Metsera has received a significantly superior offer from Novo Nordisk, valuing the company at up to $86.20 per share, a 159% premium over the pre-announcement price. This offer substantially surpasses Pfizer's revised proposal. While the Pfizer Merger Agreement is still in effect, the Board's declaration of a 'Superior Company Proposal' triggers a negotiation period, suggesting that Pfizer will likely need to increase its offer further to compete. This dynamic creates a strong likelihood of an even higher acquisition price for Metsera shareholders, making it a 'strong buy' for investors looking to capitalize on the M&A arbitrage opportunity.

Keywords

Merger, Acquisition, Tender Offer, Pharmaceutical, Biotechnology, M&A, Novo Nordisk, Pfizer, Metsera, CVR, Contingent Value Right, Drug Development, Clinical Trials, FDA Approval, MET-097i, MET-233i